Pfizer 2Q Revenues: $12.7 billion (-54%) 2Q Earnings: $2.3 billion (-77%) YTD Revenues: $31.0 billion (-42%) YTD Earnings: $7.9 billion (-56%) Comments: Primary Care revenues were down 72% to $5.8 billion in the quarter, reflecting an operational decline of $14.7 billion, or 53%, primarily due to the drop in global Paxlovid and Comirnaty revenues. Revenues from Comirnaty and Paxlovid were $1.6 billion, down 82% and 98%, respectively. Recently acquired products, Nurtec ODT/Vydura and Oxbryta...